Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic Effectiveness of Factor VIII (FVIII) Concentrates in Patients Affected by Inherited Haemophilia A With FVIII Inhibitors High and Low Anamnestic Response.

NCT01505946 is registered in ClinicalTrials.gov with Grifols Italia S.p.A as lead sponsor.

NCT NCT01505946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01505946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic Effectiveness of Factor VIII (FVIII) Concentrates in Patients Affected by Inherited Haemophilia A With FVIII Inhibitors High and Low Anamnestic Response.
Lead sponsor
Grifols Italia S.p.A
Phase
Observational
Overall status
Unknown status
Start date
March 31, 2012
Completion date
June 30, 2016
Enrollment
25 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

severe hemophilia a with inhibitor